Virology journal
Efficacy and safety of Tenofovir disoproxil fumarate (TDF) or Entecavir (ETV) combined with interferon for the treatment of chronic hepatitis B: a systematic review and meta-analysis
By Yang S, Lin Y, Yuan W and 8 others.
Abstract
Background
Whether tenofovir disoproxil fumarate (TDF) or entecavir (ETV) combined with pegylated interferon offers superior functional cure potential in chronic hepatitis B remains unclear.
Objective
To compare the efficacy and safety of TDF plus interferon versus ETV plus interferon against their respective monotherapies.
Methods
Systematic review and meta-analysis of 16 randomized controlled trials from six databases (inception to January 2026).
Interventions
TDF (300 mg/day) or ETV (0.5 mg/day) plus pegylated interferon alfa-2a/2b (180 µg/week) versus monotherapy. Primary outcomes: HBsAg reduction and HBeAg seroconversion. Risk of bias: Cochrane RoB 2; Certainty: GRADE. Prospero: CRD42025632412.